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204 Evolution of glucose intolerance in adolescent CF patients
S. Carpenter, H. Grasemann, M. Solomon. The Hospital for Sick Children, Toronto,
ON, Canada
As life expectancy for CF patients has improved, other complications such as CF-
related diabetes (CFRD) have been increasingly recognized. One would expect that as
disease progresses, a continuum of glucose intolerance ranging from normal glucose
tolerance (NGT) to impaired glucose tolerance (IGT) to CFRD would occur however
the natural history of glucose intolerance in CF is not clear.
Objective: We performed a retrospective analysis of the long-term natural history
of glucose homeostasis in an adolescent CF population. These patients were initially
evaluated prospectively by modiﬁed oral glucose tolerance testing (OGTT) at our clinic
(J Pediatr 2003;142:128−32).
Methods: Using the Toronto CF database we reviewed all of the 94 CF patients’
modiﬁed OGTT results since the time of initial testing in 1998 and categorized them
into the following classiﬁcation: NGT, IGT, CFRD without fasting hyperglycemia (FH)
and CFRD with FH.
Results: Out of the 94 patients initially studied 70 underwent subsequent OGTT testing.
The median age was 12 years (9−18 years), all were pancreatic insufﬁcient. Median
follow-up was 5 years. Overall 271 OGTTs were performed.
Conclusion: The evolution of glucose intolerance is highly variable in adolescent/young
adult CF patients. We found that 50% (8/16) patients detected to have IGT converted
back to NGT on subsequent testing. Glucose intolerance in CF patients does not
necessarily follow a continuum of NGT to IGT to CFRD as may be expected. Regular
follow-up testing is important.
Results of OGTT
Initial test 1st subsequent test
NGT IGT CFRD without FH CFRD with FH
NGT 74 37 13 0 0
IGT 16 8 2 3 4
CFRD without FH 4 0 0 3 0
CFRD with FH 0 0 0 0 0
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In patients with cystic ﬁbrosis-related diabetes (CFRD) microalbuminuria (MA) is
more common than in type 1 diabetes mellitus. In this study we investigate whether
the prevalence of MA is attributable to the fact that patients have cystic ﬁbrosis
(CF), rather than CFRD.
Study design: Cross-sectional case control study.
Subjects: The patient groups consisted of 146 adults with CF. 57 healthy adults
served as controls.
Methods: All CF patients with exocrine pancreatic insufﬁciency had a modiﬁed
oral glucose tolerance test to determine their diabetic status. A sample morning
midstream urine of each subject was analyzed for albumin-creatinine ratio (ACR).
MA was deﬁned as ACR above 2.5 for men and above 3.5 for women.
Results: Of the CF patients, 49 had CFRD, 25 had impaired glucose tolerance and
72 subjects had no signs of diabetes. Of all CFRD patients, 8 had MA (16.3%),
which was higher than in non-diabetic CF patients (p = 0.001) and healthy controls
(p = 0.002). Between the two latter groups there was no signiﬁcant difference in the
prevalence of MA. In women with CFRD, MA tended to be more frequent than in
men with CFRD (p = 0.08).
CFRD patients had a signiﬁcant higher median ACR compared to both non-diabetic
patients (p = 0.02) and healthy controls (p = 0.04). Median ACR’s were similar in
the non-diabetic CF group and the healthy controls, as were the creatinine levels.
Conclusion This study shows that CFRD patients have MA more often than non-
diabetic CF patients or healthy controls, in whom it is observed rarely. In contrast
to previous reports, our data suggest that the diabetic state rather than CF as a
disease appears to contribute to MA.
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Patients with cystic ﬁbrosis (CF) have an increased incidence of nephrolithiasis.
Because CF epithelia have ion transport abnormalities that may in part be regulated
by intracelluler calcium metabolism, and the kidney is actively involved in both
transport and calcium homeostasis, nephrocalcinosis in infants with CF probably is
evidence.
Aims: This study was to determine the frequency of hypercalciuria, and nephro-
calcinosis in CF patients.
Results: Seventy-four CF children (37 boys, 37 girls, mean age 83.7 months, range
3 months-24 years) were included in this study. Twenty-four hours urine collection
were analyzed in 42 CF patients and spot urine were analyzed in 32 CF patients.
Renal ultrasound (RU) studies were performed in all patients. Plasma electrolytes,
calcium, magnesium, phosphorus, and serum 25-hydroxyvitamine-D levels were
measured in all patients. Urine samples were examined for microscopic hematuria
and were detected in 8 CF patients. In 63 of the 74 CF patients urinary calcium
excreation was normal (less than 4mg/kg/h), 11 CF patients had hypercalciuria
(calcium excretion 4.8 to 5.2mg/kg/h). In 5 (RU) ﬁndings were abnormal. Focal
calcinosis, pelvicalicial dilatation, hyperechogenity were detected in one, one and
three patients, respectively. Patient who had focal calcinosis in (RU) was one year
old. There was no correlation between 25 hyroxyvitamine-D levels and hypercal-
ciuria. The incidence of nephrolithiasis in our study was 1.3% and hypercalciuria
was 14.86%.
Conclusion: In this study; the incidence of nephrocalcinosis in CF patients was not
found higher than normal population, different from other studies.
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In CF patients the EFA proﬁle is abnormal, and this is especially prominent in
patients with speciﬁc ‘severe’ mutations (Strandvik 2001). The abnormal EFA
proﬁle is so striking that it has been suggested to use it as an ancillary test to
support the diagnosis of CF (Batal 2007). However, limited data are available about
EFA proﬁle in CF patients with ‘mild’ mutations. Therefore a study involving EFA
chromatogram and concentration acquisition in 229 Belgian CF patients and 100
age matched controls has been designed. A GC-MS analytical method has been
selected both for its high sensitivity and speciﬁcity, using a 30m× 0.25mm ID
column after transesteriﬁcation with acetyl chloride to quantitatively analyse 28
fatty acids ranging from C12-C24. We report an interim analysis on 83 patients
(33F-50M; age range 1−55 years). Patients were classiﬁed in three groups: F508del
homozygous (n = 46), other class 1−3 mutations (n = 18), at least one class 4−5
mutation (n = 19). Fatty acid values are expressed as molar percent; means (SEM)
are reported.
Linoleic acid and DHA values were not dependent on age, sex nor serum choles-
terol concentration but signiﬁcantly correlated with mutation class (P< 0.001). As
previously reported, deﬁciency in linoleic acid and DHA is more striking in patients
with severe mutations. In patients with mild mutations the product linoleic acid x
DHA is still well below values reported in healthy controls. Therefore the value of
EFA proﬁle as an ancillary test for CF diagnosis will be further explored.
F508del/F508del Other class 1−3 One class 4−5 P group 1 vs 3
Linoleic acid 20.4 (0.6) 22.8 (1.1) 25.8 (0.6) <0.0001
DHA 1.17 (0.06) 1.26 (0.12) 1.37 (0.09) 0.08
Linoleic x DHA 24.2 (1.4) 29.0 (3.0) 35.5 (2.5) <0.001
